Skip to main content

Endothelium-dependent protein C activation in hereditary protein C deficiency.

Thrombosis and haemostasis

Authors: Nadine Schwarz, Hannah L McRae, Sara Reda, Behnaz Pezeshkpoor, Johannes Oldenburg, Jens Müller, Bernd Pötzsch, Heiko Rühl

BACKGROUND: Protein C (PC) activation on endothelial cells is a critical antithrombotic mechanism. Hereditary PC deficiency (PCD) which is caused by mutations in the PROC gene, can predispose affected individuals to thrombophilia. Previous studies investigated APC generation in PCD patients without including endothelial cells, which are essential for physiological PC activation. This study aimed to assess APC generation in PCD patients using a novel endothelial cell-based assay.

METHODS: Plasma samples from 21 patients with 19 heterozygous PROC mutations (median PC level 58%) and 24 healthy controls were analyzed. Endothelium-dependent APC generation was initiated by overlaying plasma on human umbilical vein endothelial cells (HUVECs) and adding tissue factor (1 pmol/L). APC levels were quantified using an oligonucleotide-based enzyme capture assay. The area under the curve (AUC) was calculated to monitor cumulative APC formation over time. A calibration curve generated from wild-type PC in PC-deficient plasma established reference ranges.

RESULTS: Mean peak levels of APC were significantly lower in PCD patients than in healthy controls (0.75 versus 2.00 nmol/L, P=2×10). The AUC APC was below the reference range in 8 of 21 (38%) patient samples, indicating disproportionately severe impairment in APC generation. The observed variability in APC generation suggests that endothelial contributions may identify functional differences undetected by standard PC activity or antigen assays.

CONCLUSION: This study introduces a novel endothelial cell-based APC generation assay, demonstrating the functional consequences of PROC mutations and providing insights into the regulation of APC generation, with potential applications in thrombosis risk assessment and personalized therapy.

Thieme. All rights reserved.

PMID: 40209762

Participating cluster members